Testing for CD117/c-kit expression may be a useful tool for the identification of several malignant neoplasma expressing c-kit, including gastrointestinal stromal tumors (GISTS), mast cell diseases, acute myeloid leukemia (AML), small cell lung carcinoma (SCLC), and Ewing's sarcoma. It may also aid in differentiating gastrointestinal stromal tumors (GISTS) from other intra-abdominal mesenchymal tumors. Recent studies have indicated that the tyrosine kinase inhibitor, STI571 (Gleeva), may be effective in treating CD117/c-kit positive tumors. Therefore, testing tumors for CD117/c-kit immunoreactivity can assist in both diagnosis and the prediction of drug sensitivity to tyrosine kinase inhibitor STI571 treatment.
No special preparation is needed for CD-117. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing CD-117. Your doctor depending on your condition will give specific instructions.
|UNISEX||All age groups||Test is positive if the conditions listed are detected|